Mustang Bio Reports $955,000 Net Loss in Q1 2026, Focuses on Novel Cancer Therapies

Mustang Bio, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $955,000, a significant increase from the $153,000 loss recorded in the same period of 2025. The company's total operating expenses for the quarter were approximately $1.06 million, up from $253,000 in the prior year, primarily driven by a notable increase in research and development costs. Research and development expenses amounted to $178,000, a decrease from the $964,000 reported in the previous year, largely due to non-repeat savings from the settlement of aged payables and a gain from the termination of a lease.

In terms of liquidity, Mustang Bio had cash and cash equivalents of $16.3 million as of March 31, 2026, down from $17.3 million at the end of 2025. The company has accumulated a deficit of $399.6 million since its inception and anticipates continued operating losses as it develops its product candidates. Mustang Bio has not yet generated any revenue from its product candidates, which remain in the development stage. The company is currently exploring options to raise additional capital, although it faces challenges due to its reliance on equity offerings and the limitations imposed by its existing shelf registration statements.

Strategically, Mustang Bio is focused on developing novel therapies for solid tumors, partnering with leading research institutions such as the City of Hope National Medical Center and Nationwide Children’s Hospital. The company is advancing its pipeline, which includes CAR T therapy targeting IL13Rα2 and an oncolytic virus therapy, with plans to initiate a clinical trial for a combination therapy in the third quarter of 2026. The FDA has accepted the IND application for this combination therapy, referred to as MB-109, which is aimed at treating patients with relapsed or refractory glioblastoma.

Operationally, Mustang Bio has not reported any significant changes in customer counts or user statistics, as it remains in the clinical development phase without approved products. The company continues to rely on third-party contractors for clinical trials and manufacturing, which poses risks related to performance and compliance. Additionally, Mustang Bio is currently not in compliance with certain Nasdaq listing requirements, specifically the minimum bid price rule, which could impact its stock liquidity and market value.

Looking ahead, Mustang Bio expects to incur substantial expenses related to the research and development of its product candidates and may never achieve profitability. The company believes it has sufficient cash to fund operations for at least the next twelve months but acknowledges the uncertainty surrounding its ability to secure additional funding. The management remains focused on advancing its clinical programs and addressing the challenges posed by market conditions and regulatory requirements.